Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 12/2013

01-12-2013 | Systematic Review

The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review

Authors: Michael Sonntag, Hans-Helmut König, Alexander Konnopka

Published in: PharmacoEconomics | Issue 12/2013

Login to get access

Abstract

Objective

To systematically review approaches and instruments used to derive utility weights in cost-utility analyses (CUAs) within the field of mental disorders and to identify factors that may have influenced the choice of the approach.

Methods

We searched the databases DARE (Database of Abstracts of Reviews of Effects), NHS EED (National Health Service Economic Evaluation Database), HTA (Health Technology Assessment), and PubMed for CUAs. Studies were included if they were full economic evaluations and reported quality-adjusted life-years as the health outcome. Study characteristics and instruments used to estimate utility weights were described and a logistic regression analysis was conducted to identify factors associated with the choice of either the direct (e.g. standard gamble) or the preference-based measure (PBM) approach (e.g. EQ-5D).

Results

We identified 227 CUAs with a maximum in 2009, 2010, and 2012. Most CUAs were conducted in depression, dementia, or psychosis, and came from the US or the UK, with the EQ-5D being the most frequently used instrument. The application of the direct approach was significantly associated with depression, psychosis, and model-based studies. The PBM approach was more likely to be used in recent studies, dementia, Europe, and empirical studies. Utility weights used in model-based studies were derived from only a small number of studies.

Limitations

We only searched four databases and did not evaluate the quality of the included studies.

Conclusions

Direct instruments and PBMs are used to elicit utility weights in CUAs with different frequencies regarding study type, mental disorder, and country.
Appendix
Available only for authorised users
Literature
1.
Drummond MF, Sculpher MF, Torrance GW, O‘Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
2.
Brazier J, Deverill M, Green C, Harper R, Booth A. A review of the use of health status measures in economic evaluation. Health Technol Assess. 1999;3(9):i–iv, 1–164.
3.
Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2007.
4.
Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11(2):215–25.PubMed
5.
Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(14):1172–7.PubMed
6.
Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. JAMA. 1996;276(16):1339–41.
7.
Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253–8.PubMed
8.
Chisholm D, Healey A, Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol. 1997;32(1):68–75.PubMed
9.
Flood C. Should “standard gamble” and “time trade off” utility measurement be used more in mental health research? J Ment Health Policy Econ. 2010;13(2):65–72.
10.
König HH. Measuring preferences of psychiatric patients. Psychiatr Prax. 2004;31(3):118–27.PubMed
11.
Mavranezouli I. A review and critique of studies reporting utility values for schizophrenia-related health states. Pharmacoeconomics. 2010;28(12):1109–21.PubMed
12.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.PubMed
13.
Gerhards SA, de Graaf LE, Jacobs LE, Severens JL, Huibers MJ, Arntz A, et al. Economic evaluation of online computerised cognitive-behavioural therapy without support for depression in primary care: randomised trial. Br J Psychiatry. 2010;196(4):310–8.PubMed
14.
Joesch JM, Sherbourne CD, Sullivan G, Stein MB, Craske MG, Roy-Byrne P. Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care. Psychol Med. 2012;42(9):1937–48.PubMed
15.
Jonkers CC, Lamers F, Evers SM, Bosma H, Metsemakers JF, Van Eijk JT. Economic evaluation of a minimal psychological intervention in chronically ill elderly patients with minor or mild to moderate depression: a randomized trial (the DELTA-study). Int J Technol Assess Health Care. 2009;25(4):497–504.PubMed
16.
Patel A, McCrone P, Leese M, Amaddeo F, Tansella M, Kilian R, et al. Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries. Cost Eff Resour Alloc. 2013;11(1):12.PubMed
17.
Pyne JM, Fortney JC, Tripathi SP, Maciejewski ML, Edlund MJ, Williams DK. Cost-effectiveness analysis of a rural telemedicine collaborative care intervention for depression. Arch Gen Psychiatry. 2010;67(8):812–21.PubMed
18.
Perlis RH, Patrick A, Smoller JW, Wang PS. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology. 2009;34(10):2227–36.PubMed
19.
Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone. Psychopharmacol Bull. 1995;31(2):9.
20.
Ascher-Svanum H, Stensland MD, Peng X, Faries DE, Stauffer VL, Osuntokun OO, et al. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Curr Med Res Opin. 2011;27(1):115–22.PubMed
21.
Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ. 2012;15(3):531–47.PubMed
22.
Benedict A, Arellano J, De Cock E, Baird J. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland. J Affect Disord. 2010;120(1–3):94–104.PubMed
23.
Campbell S, Norris S, Standfield L, Suebwongpat A. Screening for postnatal depression within the Well Child Tamariki Ora Framework. Health Services Assessment Collaboration Report. 2008;1(2).
24.
Canadian Coordinating Office for Health Technology Assessment. A clinical and economic evaluation of selective serotonin reuptake inhibitors in major depression. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 1997.
25.
Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol. 1997;17(4):298–307.PubMed
26.
Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, et al. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom. Value Health. 2008;11(3):376–88.PubMed
27.
Damen J, Thuresson PO, Heeg B, Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Appl Health Econ Health Policy. 2008;6(4):189–97.PubMed
28.
Ekman M, Lindgren P, Miltenburger C, Meier G, Locklear JC, Chatterton ML. Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode. Pharmacoeconomics. 2012;30(6):513–30.PubMed
29.
Faber A, van Agthoven M, Kalverdijk LJ, Tobi H, de Jong-van den Berg LT, Annemans L, et al. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS Drugs. 2008;22(2):157–70.
30.
Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc. 2009;7:4.PubMed
31.
Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Current Med Res Opinion. 2011;27(4):17.
32.
Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012;15(1):55–64.PubMed
33.
Hong J, Dilla T, Arellano J. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain. BMC Psychiatry. 2009;9:15.PubMed
34.
Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J. A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. Health Technol Assess. 2002;6(22):1–89.PubMed
35.
Kapoor A, Kraemer KL, Smith KJ, Roberts MS, Saitz R. Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model. Alcohol Clin Exp Res. 2009;33(8):1440–9.PubMed
36.
King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess. 2006;10(23):iii–iv, xiii–146.
37.
Kirbach S, Simpson K, Nietert PJ, Mintzer J. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer’s disease. Clin Drug Investig. 2008;28(5):291–303.PubMed
38.
Leelahanaj T. The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model. J Med Assoc Thai. 2010;93(Suppl 6):S43–50.PubMed
39.
Leelahanaj T. Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder. J Med Assoc Thai. 2010;93(Suppl 6):S35–42.PubMed
40.
Mavissakalian MR, Schmier JK, Flynn JA, Revicki DA. Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder. Pharmacoeconomics. 2000;18(4):383–91.PubMed
41.
Nuijten MJ. Assessment of clinical guidelines for continuation treatment in major depression. Value Health. 2001;4(4):281–94.PubMed
42.
Oh P, Lanctôt KL, Mittmann N, Iskedjian M, Einarson TR. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. J Med Econ. 2001;4:137–56.
43.
Oh PI, Iskedjian M, Addis A, Lanctot K, Einarson TR. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol. Winter. 2001;8(4):199–206.
44.
Paulden M, Palmer S, Hewitt C, Gilbody S. Screening for postnatal depression in primary care: cost effectiveness analysis. BMJ. 2009;339:b5203.PubMed
45.
Prasad S, Arellano J, Steer C, Libretto SE. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK. Int J Clin Pract. 2009;63(7):1031–40.PubMed
46.
Revicki DA, Brown RE, Palmer W, Bakish D, Rosser WW, Anton SF, et al. Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics. 1995;8(6):16.
47.
Revicki DA, Brown RE, Keller MB, Gonzales J, Culpepper L, Hales RE. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry. 1997;58(2):11.
48.
Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, et al. Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust N Z J Psychiatry. 2009;43(6):539–47.PubMed
49.
Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry. 2011;12(7):501–15.PubMed
50.
Simon J, Pilling S, Burbeck R, Goldberg D. Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. Br J Psychiatry. 2006;189:494–501.PubMed
51.
Simpson KN, Welch MJ, Kozel FA, Demitrack MA, Nahas Z. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis. Adv Ther. 2009;26(3):346–68.PubMed
52.
Treur M, Heeg B, Moller HJ, Schmeding A, van Hout B. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. BMC Health Serv Res. 2009;9:32.PubMed
53.
Valenstein M, Vijan S, Zeber JE, Boehm K, Buttar A. The cost-utility of screening for depression in primary care. Ann Intern Med. 2001;134(5):345–60.PubMed
54.
Wang PS, Ganz DA, Benner JS, Glynn RJ, Avorn J. Should clozapine continue to be restricted to third-line status for schizophrenia? A decision-analytic model. J Ment Health Policy Econ. 2004;7(2):77–85.PubMed
55.
Wang PS, Patrick A, Avorn J, Azocar F, Ludman E, McCulloch J, et al. The costs and benefits of enhanced depression care to employers. Arch Gen Psychiatry. 2006;63(12):1345–53.PubMed
56.
Aziz M, Mehringer AM, Mozurkewich E, Razik GN. Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model. Can J Psychiatry. 2005;50(7):389–97.PubMed
57.
Einarson TR, Geitona M, Chaidemenos A, Karpouza V, Mougiakos T, Paterakis P, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. Ann Gen Psychiatry. 2012;11(1):18.PubMed
58.
Einarson TR, Pudas H, Zilbershtein R, Jensen R, Vicente C, Piwko C, et al. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. J Med Econ. 2013;16(9):1096–105.PubMed
59.
Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ. 2012;15(5):844–61.PubMed
60.
Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, et al. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics. 2012;30(8):e1–15.PubMed
61.
Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease: a simulation study. Curr Alzheimer Res. 2013;10(2):207–16.PubMed
62.
Cheema N, Frangou F, McCrone P. Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder. Ther Adv Psychopharmacol. 2013;3(2):73–81.PubMed
63.
McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract. 2010;16(4):744–55.PubMed
64.
Soares-Weiser K, Bravo Vergel Y, Beynon S, Dunn G, Barbieri M, Duffy S, et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess. 2007;11(39):iii–iv, ix–206.
65.
Lindner LM, Marasciulo AC, Farias MR, Grohs GE. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. Rev Saude Publica. 2009;43(Suppl 1):62–9.PubMed
66.
Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, et al. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005;25(5):427–34.PubMed
67.
Wimo A, Mattson B, Krakau I, Eriksson T, Nelvig A, Karlsson G. Cost-utility analysis of group living in dementia care. Int J Technol Assess Health Care. 1995;11(1):16.
68.
Armstrong EP, Skrepnek GH, Haim Erder M M. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2007;23(2):251–8.PubMed
69.
Barbosa C, Taylor B, Godfrey C, Rehm J, Parrott S, Drummond C. Modelling lifetime QALYs and health care costs from different drinking patterns over time: a Markov model. Int J Methods Psychiatr Res. 2010;19(2):97–109.PubMed
70.
Barton GR, Hodgekins J, Mugford M, Jones PB, Croudace T, Fowler D. Cognitive behaviour therapy for improving social recovery in psychosis: cost-effectiveness analysis. Schizophr Res. 2009;112(1–3):158–63.PubMed
71.
Blankers M, Nabitz U, Smit F, Koeter MW, Schippers GM. Economic evaluation of internet-based interventions for harmful alcohol use alongside a pragmatic randomized controlled trial. J Med Internet Res. 2012;14(5):e134.PubMed
72.
Bodden DH, Dirksen CD, Bogels SM, Nauta MH, De Haan E, Ringrose J, et al. Costs and cost-effectiveness of family CBT versus individual CBT in clinically anxious children. Clin Child Psychol Psychiatry. 2008;13(4):543–64.PubMed
73.
Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012;16(21):1–470.PubMed
74.
Bosmans J, de Bruijne M, van Hout H, van Marwijk H, Beekman A, Bouter L, et al. Cost-effectiveness of a disease management program for major depression in elderly primary care patients. J Gen Intern Med. 2006;21(10):1020–6.PubMed
75.
Bosmans JE, van Schaik DJ, Heymans MW, van Marwijk HW, van Hout HP, de Bruijne MC. Cost-effectiveness of interpersonal psychotherapy for elderly primary care patients with major depression. Int J Technol Assess Health Care. 2007 Fall;23(4):480–7.
76.
Bosmans JE, Hermens ML, de Bruijne MC, van Hout HP, Terluin B, Bouter LM, et al. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression. J Affect Disord. 2008;111(1):106–12.PubMed
77.
Bosmans JE, Schreuders B, van Marwijk HW, Smit JH, van Oppen P, van Tulder MW. Cost-effectiveness of problem-solving treatment in comparison with usual care for primary care patients with mental health problems: a randomized trial. BMC Fam Pract. 2012;13:98.PubMed
78.
Bosmans JE, Dozeman E, van Marwijk HW, van Schaik DJ, Stek ML, Beekman AT, et al. Cost-effectiveness of a stepped care programme to prevent depression and anxiety in residents in homes for the older people: a randomised controlled trial. Int J Geriatr Psychiatry. Epub 13 June 2013.
79.
Byford S, Knapp M, Greenshields J, Ukoumunne OC, Jones V, Thompson S, et al. Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach. Psychol Med. 2003;33(6):977–86.PubMed
80.
Byford S, Barrett B, Roberts C, Wilkinson P, Dubicka B, Kelvin RG, et al. Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression. Br J Psychiatry. 2007;191:521–7.PubMed
81.
Chalder M, Wiles NJ, Campbell J, Hollinghurst SP, Searle A, Haase AM, et al. A pragmatic randomised controlled trial to evaluate the cost-effectiveness of a physical activity intervention as a treatment for depression: the treating depression with physical activity (TREAD) trial. Health Technol Assess. 2012;16(10):1–164, iii–iv.
82.
Charlesworth G, Shepstone L, Wilson E, Thalanany M, Mugford M, Poland F. Does befriending by trained lay workers improve psychological well-being and quality of life for carers of people with dementia, and at what cost? A randomised controlled trial. Health Technol Assess. 2008;12(4):iii, v–ix, 1–78.
83.
Crawford MJ, Killaspy H, Barnes TR, Barrett B, Byford S, Clayton K, et al. Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE). Health Technol Assess. 2012;16(8):iii–iv, 1–76.
84.
Davidson KM, Tyrer P, Norrie J, Palmer SJ, Tyrer H. Cognitive therapy v. usual treatment for borderline personality disorder: prospective 6-year follow-up. Br J Psychiatry. 2010;197(6):456–62.PubMed
85.
Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry. 2007;191:14–22.PubMed
86.
Davies LM, Barnes TR, Jones PB, Lewis S, Gaughran F, Hayhurst K, et al. A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. Value Health. 2008;11(4):549–62.PubMed
87.
De Ridder A, De Graeve D. Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach. Pharmacoeconomics. 2009;27(1):69–80.PubMed
88.
De Salas-Cansado M, Olivares JM, Alvarez E, Carrasco JL, Barrueta A, Rejas J. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain. Clinicoecon Outcomes Res. 2012;4:157–68.PubMed
89.
Dijkgraaf MG, van der Zanden BP, de Borgie CA, Blanken P, van Ree JM, van den Brink W. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ. 2005;330(7503):1297.PubMed
90.
Drummond C, Coulton S, James D, Godfrey C, Parrott S, Baxter J, et al. Effectiveness and cost-effectiveness of a stepped care intervention for alcohol use disorders in primary care: pilot study. Br J Psychiatry. 2009;195(5):448–56.PubMed
91.
Ekers D, Godfrey C, Gilbody S, Parrott S, Richards DA, Hammond D, et al. Cost utility of behavioural activation delivered by the non-specialist. Br J Psychiatry. 2011;199(6):510–1.PubMed
92.
Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, et al. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy. 2012;10(6):381–95.PubMed
93.
Furze G, Dumville JC, Miles JN, Irvine K, Thompson DR, Lewin RJ. “Prehabilitation” prior to CABG surgery improves physical functioning and depression. Int J Cardiol. 2009;132(1):51–8.PubMed
94.
Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52(8):519–26.PubMed
95.
Gensichen J, Petersen JJ, Von Korff M, Heider D, Baron S, Konig J, et al. Cost-effectiveness of depression case management in small practices. Br J Psychiatry. 2013;202:441–6.PubMed
96.
Getsios D, Blume S, Ishak KJ, Maclaine GD. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer’s disease: a UK evaluation using discrete-event simulation. Pharmacoeconomics. 2010;28(5):411–27.PubMed
97.
Getsios D, Blume S, Ishak KJ, Maclaine G, Hernandez L. An economic evaluation of early assessment for Alzheimer’s disease in the United Kingdom. Alzheimers Dement. 2012;8(1):22–30.PubMed
98.
Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, et al. A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess. 2008;12(14):iii–iv, ix–60.
99.
Gusi N, Reyes MC, Gonzalez-Guerrero JL, Herrera E, Garcia JM. Cost-utility of a walking programme for moderately depressed, obese, or overweight elderly women in primary care: a randomised controlled trial. BMC Public Health. 2008;8:231.PubMed
100.
Guthrie E, Moorey J, Margison F, Barker H, Palmer S, McGrath G, et al. Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services. Arch Gen Psychiatry. 1999;56(6):519–26.PubMed
101.
Hartz S, Getsios D, Tao S, Blume S, Maclaine G. Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer’s disease in Germany using discrete event simulation. BMC Neurol. 2012;12:2.PubMed
102.
Hedman E, Andersson E, Ljotsson B, Andersson G, Ruck C, Lindefors N. Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial. Behav Res Ther. 2011;49(11):729–36.PubMed
103.
Hollinghurst S, Peters TJ, Kaur S, Wiles N, Lewis G, Kessler D. Cost-effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: randomised controlled trial. Br J Psychiatry. 2010;197(4):297–304.PubMed
104.
Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging. 2004;21(9):607–20.PubMed
105.
Jönsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer’s disease in Sweden. Am J Geriatr Pharmacother. 2005;3(2):77–86.PubMed
106.
Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, et al. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technol Assess. 2006;10(33):iii, xi–xiv, 1–168.
107.
Karow A, Reimer J, Konig HH, Heider D, Bock T, Huber C, et al. Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry. 2012;73(3):e402–8.PubMed
108.
Kendrick T, Simons L, Mynors-Wallis L, Gray A, Lathlean J, Pickering R, et al. A trial of problem-solving by community mental health nurses for anxiety, depression and life difficulties among general practice patients. The CPN-GP study. Health Technol Assess. 2005;9(37):1–104, iii.
109.
Kendrick T, Peveler R, Longworth L, Baldwin D, Moore M, Chatwin J, et al. Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine: randomised controlled trial. Br J Psychiatry. 2006;188:337–45.PubMed
110.
Kim BR, Lee TJ, Lee HJ, Park BH, Yang BM. Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea. Value Health Reg Issues. 2012;1(1):59–65.
111.
Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics. 2008;26(4):341–58.PubMed
112.
König HH, Born A, Heider D, Matschinger H, Heinrich S, Riedel-Heller SG, et al. Cost-effectiveness of a primary care model for anxiety disorders. Br J Psychiatry. 2009;195(4):308–17.PubMed
113.
Kuo YC, Lan CF, Chen LK, Lan VM. Dementia care costs and the patient’s quality of life (QoL) in Taiwan: home versus institutional care services. Arch Gerontol Geriatr. 2010;51(2):159–63.PubMed
114.
Lambert RA, Lorgelly P, Harvey I, Poland F. Cost-effectiveness analysis of an occupational therapy-led lifestyle approach and routine general practitioner’s care for panic disorder. Soc Psychiatry Psychiatr Epidemiol. 2010;45(7):741–50.PubMed
115.
Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess. 2006;10(17):iii–iv, ix–xi, 1–165.
116.
Lindström E, Eberhard J, Fors BM, Hansen K, Sapin C. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry. 2011;65(6):403–13.PubMed
117.
Lopez-Bastida J, Hart W, Garcia-Perez L, Linertova R. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. J Alzheimers Dis. 2009;16(2):399–407.PubMed
118.
Maniadakis N, Kourlaba G, Mougiakos T, Chatzimanolis I, Jonsson L. Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece. BMC Health Serv Res. 2013;13:173.PubMed
119.
Mansdotter AM, Rydberg MK, Wallin E, Lindholm LA, Andreasson S. A cost-effectiveness analysis of alcohol prevention targeting licensed premises. Eur J Public Health. 2007;17(6):618–23.PubMed
120.
Mencacci C, Di Sciascio G, Katz P, Ripellino C. Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy. Clinicoecon Outcomes Res. 2013;5:87–99.PubMed
121.
Nordström G, Despiegel N, Marteau F, Danchenko N, Maman K. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden. J Med Econ. 2010;13(3):10.
122.
Nordström G, Danchenko N, Despiegel N, Marteau F. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder. Value Health. 2012;15(2):231–9.PubMed
123.
Nosyk B, Guh DP, Bansback NJ, Oviedo-Joekes E, Brissette S, Marsh DC, et al. Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment. CMAJ. 2012;184(6):E317–28.PubMed
124.
Palmer S, Davidson K, Tyrer P, Gumley A, Tata P, Norrie J, et al. The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial. J Pers Disord. 2006;20(5):466–81.PubMed
125.
Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, et al. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005;9(16):1–134, iii.
126.
Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction. 2010;105(9):1616–24.PubMed
127.
Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One. 2012;7(8):e42003.PubMed
128.
Rive B, Aarsland D, Grishchenko M, Cochran J, Lamure M, Toumi M. Cost-effectiveness of memantine in moderate and severe Alzheimer’s disease in Norway. Int J Geriatr Psychiatry. 2012;27(6):573–82.PubMed
129.
Romeo R, Knapp M, Hellier J, Dewey M, Ballard C, Baldwin R, et al. Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. Br J Psychiatry. 2013;202:121–8.PubMed
130.
Scott GW, Scott HM, O’Keeffe KM, Gander PH. Insomnia—treatment pathways, costs and quality of life. Cost Eff Resour Alloc. 2011;9:10.PubMed
131.
Serrano-Blanco A, Pinto-Meza A, Suarez D, Penarrubia MT, Haro JM. Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia. Acta Psychiatr Scand Suppl. 2006;432:39–47.PubMed
132.
Serrano-Blanco A, Suarez D, Pinto-Meza A, Penarrubia MT, Haro JM. Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care? J Eval Clin Pract. 2009;15(1):195–203.
133.
Shearer J, Shanahan M, Darke S, Rodgers C, van Beek I, McKetin R, et al. A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence. Drug Alcohol Rev. 2010;29(3):235–42.PubMed
134.
Silva Miguel L, Silva Miguel N, Ines M. A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal. Cost Eff Resour Alloc. 2013;11(1):8.PubMed
135.
Smith KJ, Baik SH, Reynolds CF 3rd, Rollman BL, Zhang Y. Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder. Am J Manag Care. 2013;19(2):e55–63.PubMed
136.
Sobocki P, Ekman M, Agren H, Jonsson B, Rehnberg C. Model to assess the cost-effectiveness of new treatments for depression. Int J Technol Assess Health Care. 2006 Fall;22(4):469–77.
137.
Sobocki P, Ekman M, Ovanfors A, Khandker R, Jonsson B. The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder. Int J Clin Pract. 2008;62(4):623–32.PubMed
138.
Soeteman DI, Verheul R, Delimon J, Meerman AM, van den Eijnden E, Rossum BV, et al. Cost-effectiveness of psychotherapy for cluster B personality disorders. Br J Psychiatry. 2010;196(5):396–403.PubMed
139.
Soeteman DI, Verheul R, Meerman AM, Ziegler U, Rossum BV, Delimon J, et al. Cost-effectiveness of psychotherapy for cluster C personality disorders: a decision-analytic model in the Netherlands. J Clin Psychiatry. 2011;72(1):51–9.PubMed
140.
Solomon D, Adams J, Graves N. Economic evaluation of St. John’s wort (Hypericum perforatum) for the treatment of mild to moderate depression. J Affect Disord. 2013;148(2–3):228–34.PubMed
141.
Stant AD, TenVergert EM, Wunderink L, Nienhuis FJ, Wiersma D. Economic consequences of alternative medication strategies in first episode non-affective psychosis. Eur Psychiatry. 2007;22(6):347–53.PubMed
142.
Stant AD, TenVergert EM, Kluiter H, Conradi HJ, Smit A, Ormel J. Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care. J Mental Health Policy Econ. 2009;12(4):9.
143.
Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18(13):911–32.PubMed
144.
Ukatt RT. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005;331(7516):544.
145.
Underwood M, Lamb SE, Eldridge S, Sheehan B, Slowther A, Spencer A, et al. Exercise for depression in care home residents: a randomised controlled trial with cost-effectiveness analysis (OPERA). Health Technol Assess. 2013;17(18):1–281.PubMed
146.
van Asselt AD, Dirksen CD, Arntz A, Giesen-Bloo JH, van Dyck R, Spinhoven P, et al. Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy. Br J Psychiatry. 2008;192(6):450–7.PubMed
147.
van Roijen LH, van Straten A, Al M, Rutten F, Donker M. Cost-utility of brief psychological treatment for depression and anxiety. Br J Psychiatry. 2006;188:323–9.PubMed
148.
Vera-Llonch M, Dukes E, Rejas J, Sofrygin O, Mychaskiw M, Oster G. Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ. 2010;11(1):35–44.PubMed
149.
Warmerdam L, Smit F, van Straten A, Riper H, Cuijpers P. Cost-utility and cost-effectiveness of internet-based treatment for adults with depressive symptoms: randomized trial. J Med Internet Res. 2010;12(5):e53.PubMed
150.
Wilson E, Thalanany M, Shepstone L, Charlesworth G, Poland F, Harvey I, et al. Befriending carers of people with dementia: a cost utility analysis. Int J Geriatr Psychiatry. 2009;24(6):610–23.PubMed
151.
Wolfs CA, Dirksen CD, Kessels A, Severens JL, Verhey FR. Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial. Arch Gen Psychiatry. 2009;66(3):313–23.PubMed
152.
Zhang Y, Kivipelto M, Solomon A, Wimo A. Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting. J Alzheimers Dis. 2011;26(4):735–44.PubMed
153.
Berghout CC, Zevalkink J, Hakkaart-van Roijen L. A cost-utility analysis of psychoanalysis versus psychoanalytic psychotherapy. Int J Technol Assess Health Care. 2010;26(1):3–10.PubMed
154.
Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm. 2006;12(4):322–30.PubMed
155.
Dietl M, Kornhuber J, Schoffski O, Grassel E. Cost-effectiveness model of a community-based service for dementia caregivers. Gesundheitswesen. 2010;72(2):99–105.PubMed
156.
Fajutrao LMM, Paulsson B, Liu S, Locklear J. Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Clin Ther. 2009;31(1):12.
157.
Francois C, Montgomery SA, Despiegel N, Aballea S, Roiz J, Auquier P. Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. Int J Clin Pract. 2008;62(11):1693–702.PubMed
158.
Hay JW, Katon WJ, Ell K, Lee PJ, Guterman JJ. Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes. Value Health. 2012;15(2):249–54.PubMed
159.
Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, et al. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study. Health Technol Assess. 2009;13(22):iii–iv, ix–xi, 1–159.
160.
Knapp M, Romeo R, Mogg A, Eranti S, Pluck G, Purvis R, et al. Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: a multi-centre randomised controlled trial. J Affect Disord. 2008;109(3):273–85.PubMed
161.
McLoughlin DM, Mogg A, Eranti S, Pluck G, Purvis R, Edwards D, et al. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. Health Technol Assess. 2007;11(24):1–54.PubMed
162.
Morgan K, Dixon S, Mathers N, Thompson J, Tomeny M. Psychological treatment for insomnia in the regulation of long-term hypnotic drug use. Health Technol Assess. 2004;8(8):iii–iv, 1–68.
163.
Morrell CJ, Warner R, Slade P, Dixon S, Walters S, Paley G, et al. Psychological interventions for postnatal depression: cluster randomised trial and economic evaluation. The PoNDER trial. Health Technol Assess. 2009;13(30):iii–iv, xi–xiii, 1–153.
164.
Mukuria C, Brazier J, Barkham M, Connell J, Hardy G, Hutten R, et al. Cost-effectiveness of an improving access to psychological therapies service. Br J Psychiatry. 2013;202(3):220–7.PubMed
165.
O’Keeffe KM, Gander PH, Scott WG, Scott HM. Insomnia treatment in New Zealand. N Z Med J. 2012;125(1349):46–59.PubMed
166.
Pyne JM, Rost KM, Zhang M, Williams DK, Smith J, Fortney J. Cost-effectiveness of a primary care depression intervention. J Gen Intern Med. 2003;18(6):432–41.PubMed
167.
Pyne JM, Smith J, Fortney J, Zhang M, Williams DK, Rost K. Cost-effectiveness of a primary care intervention for depressed females. J Affect Disord. 2003;74(1):23–32.PubMed
168.
Pyne JM, Rost KM, Farahati F, Tripathi SP, Smith J, Williams DK, et al. One size fits some: the impact of patient treatment attitudes on the cost-effectiveness of a depression primary-care intervention. Psychol Med. 2005;35(6):839–54.PubMed
169.
van Ravesteijn H, Grutters J, olde Hartman T, Lucassen P, Bor H, van Weel C, et al. Mindfulness-based cognitive therapy for patients with medically unexplained symptoms: a cost-effectiveness study. J Psychosom Res. 2013;74(3):197–205.
170.
Walters D, Connor JP, Feeney GF, Young RM. The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence. J Addict Dis. 2009;28(2):137–44.PubMed
171.
Woodward TC, Tafesse E, Quon P, Kim J, Lazarus A. Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder. J Med Econ. 2009;12(4):259–68.PubMed
172.
Woodward TC, Tafesse E, Quon P, Lazarus A. Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics. 2010;28(9):751–64.PubMed
173.
Caro JJ, Salas M, Ward A, Getsios D, Mehnert A. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer’s disease in the Netherlands. Dement Geriatr Cogn Disord. 2002;14(2):84–9.PubMed
174.
Caro J, Salas M, Ward A, Getsios D, Migliaccio-Walle K, Garfield F. Assessing the health and economic impact of galantamine treatment in patients with Alzheimer’s disease in the health care systems of different countries. Drugs Aging. 2004;21(10):677–86.PubMed
175.
Fuh JL, Wang SJ. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer’s disease in Taiwan. Int J Geriatr Psychiatry. 2008;23(1):73–8.PubMed
176.
Getsios D, Caro JJ, Caro G, Ishak K. Assessment of health economics in Alzheimer’s disease (AHEAD): galantamine treatment in Canada. Neurology. 2001;57(6):972–8.PubMed
177.
Green C, Picot J, Loveman E, Takeda A, Kirby J, Clegg A. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease. Pharmacoeconomics. 2005;23(12):1271–82.PubMed
178.
Happich M, Schweikert B, Muhlbacher A. Cost-effectiveness of galantamine in a german context. Psychiatr Prax. 2005;32(3):142–50.PubMed
179.
Ikeda S, Yamada Y, Ikegami N. Economic evaluation of donepezil treatment for Alzheimer’s disease in Japan. Dement Geriatr Cogn Disord. 2002;13(1):33–9.PubMed
180.
Kasuya M, Meguro K. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer’s disease as shown by the Markov model. Arch Gerontol Geriatr. 2010;50(3):295–9.PubMed
181.
Kozel FA, George MS, Simpson KN. Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. CNS Spectr. 2004;9(6):476–82.PubMed
182.
Kulasingam SL, Samsa GP, Zarin DA, Rutschmann OT, Patwardhan MB, McCrory DC, et al. When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer’s dementia? A decision analysis. Value Health. 2003;6(5):542–50.PubMed
183.
Lachaine J, Beauchemin C, Legault M, Bineau S. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):596–604.PubMed
184.
Martikainen J, Valtonen H, Pirttila T. Potential cost-effectiveness of a family-based program in mild Alzheimer’s disease patients. Eur J Health Econ. 2004;5(2):136–42.PubMed
185.
McMahon PM, Araki SS, Neumann PJ, Harris GJ, Gazelle GS. Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease. Radiology. 2000;217(1):58–68.PubMed
186.
McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology. 2003;228(2):515–22.PubMed
187.
Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology. 1999;52(6):1138–45.PubMed
188.
Payne K, Davies LM, Noyce PR, Weiss MC. The value of the managed entry of new drugs: a case study of donepezil. Int J Technol Assess Health Care. 2003 Winter;19(1):114–28.
189.
Pfeil AM, Kressig RW, Szucs TD. Alzheimer’s dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland. Swiss Med Wkly. 2012;142:w13676.PubMed
190.
Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, et al. Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. Arch Gen Psychiatry. 2007;64(11):1259–68.PubMed
191.
Suh GH. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer’s disease in Korea. Value Health. 2009;12 Suppl 3:S49–54.PubMed
192.
Teipel SJ, Ewers M, Reisig V, Schweikert B, Hampel H, Happich M. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2007;257(6):330–6.PubMed
193.
Touchon J, Lachaine J, Beauchemin C, Granghaud A, Rive B, Bineau S. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ. Epub 9 Aug 2013.
194.
Ward A, Caro JJ, Getsios D, Ishak K, O’Brien J, Bullock R. Assessment of health economics in Alzheimer’s disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry. 2003;18(8):740–7.PubMed
195.
Pitkala KH, Laurila JV, Strandberg TE, Kautiainen H, Sintonen H, Tilvis RS. Multicomponent geriatric intervention for elderly inpatients with delirium: effects on costs and health-related quality of life. J Gerontol A Biol Sci Med Sci. 2008;63(1):56–61.PubMed
196.
Pohjolainen V, Rasanen P, Roine RP, Sintonen H, Wahlbeck K, Karlsson H. Cost-utility of treatment of bulimia nervosa. Int J Eat Disord. 2010;43(7):596–602.PubMed
197.
Wang LY, Nichols LP, Austin SB. The economic effect of Planet Health on preventing bulimia nervosa. Arch Pediatr Adolesc Med. 2011;165(8):756–62.PubMed
198.
Gournay K, Brooking J. The community psychiatric nurse in primary care: an economic analysis. J Adv Nurs. 1995;22(4):769–78.PubMed
199.
Lintvedt OK, Griffiths KM, Eisemann M, Waterloo K. Evaluating the translation process of an Internet-based self-help intervention for prevention of depression: a cost-effectiveness analysis. J Med Internet Res. 2013;15(1):e18.PubMed
200.
Wilkinson G, Croft-Jeffreys C, Krekorian H, McLees S, Falloon I. QALYs in psychiatric care? Psychiatr Bull. 1990;14:582–5.
201.
Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005;23(1):77–91.PubMed
202.
Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia. Birmingham: Development and Evaluation Service Department of Public Health and Epidemiology; 1998.
203.
Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf. 2001;10(2):85–94.PubMed
204.
Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess. 2005;9(9):1–156, iii–iv.
205.
Drummond MF, Mohide EA, Tew M, Streiner DL, Pringle DM, Gilbert JR. Economic evaluation of a support program for caregivers of demented elderly. Int J Technol Assess Health Care. 1991;7(2):10.
206.
Narayan S, Hay J. Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Rev Pharmacoecon Outcomes Res. 2004;4(6):625–34.PubMed
207.
Botteman MF, Ozminkowski RJ, Wang S, Pashos CL, Schaefer K, Foley DJ. Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs. 2007;21(4):319–34.PubMed
208.
Brazier J, Tumur I, Holmes M, Ferriter M, Parry G, Dent-Brown K, et al. Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation. Health Technol Assess. 2006;10(35):iii, ix–xii, 1–117.
209.
Domino ME, Burns BJ, Silva SG, Kratochvil CJ, Vitiello B, Reinecke MA, et al. Cost-effectiveness of treatments for adolescent depression: results from TADS. Am J Psychiatry. 2008;165(5):588–96.PubMed
210.
Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, et al. Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry. 2009;48(7):711–20.PubMed
211.
Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, et al. The cost-effectiveness of atypicals in the UK. Value Health. 2008;11(7):1007–21.PubMed
212.
Hensen M, Heeg B, Lothgren M, van Hout B. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy. 2010;8(5):327–41.PubMed
213.
Järbrink K, Kreif N, Benedict A, Locklear J. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin. 2009;25(3):709–16.PubMed
214.
Katon WJ, Schoenbaum M, Fan MY, Callahan CM, Williams J Jr, Hunkeler E, et al. Cost-effectiveness of improving primary care treatment of late-life depression. Arch Gen Psychiatry. 2005;62(12):1313–20.PubMed
215.
Katon W, Unutzer J, Fan MY, Williams JW Jr, Schoenbaum M, Lin EH, et al. Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression. Diabetes Care. 2006;29(2):265–70.PubMed
216.
Katon W, Russo J, Sherbourne C, Stein MB, Craske M, Fan MY, et al. Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med. 2006;36(3):353–63.PubMed
217.
Laux G, Heeg B, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics. 2005;23(Suppl 1):49–61.PubMed
218.
Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry. 1998;55(7):645–51.PubMed
219.
Lenox-Smith A, Greenstreet L, Burslem K, Knight C. Cost effectiveness of venlafaxine compared with generic fluoxetine of generic amitriptyline in major depressive disorder in the UK. Clin Drug Investig. 2009;29(3):11.
220.
Lynch FL, Hornbrook M, Clarke GN, Perrin N, Polen MR, O’Connor E, et al. Cost-effectiveness of an intervention to prevent depression in at-risk teens. Arch Gen Psychiatry. 2005;62(11):1241–8.PubMed
221.
Lynch FL, Dickerson JF, Clarke G, Vitiello B, Porta G, Wagner KD, et al. Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry. 2011;68(3):253–62.PubMed
222.
McCrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, et al. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry. 2004;185:55–62.PubMed
223.
Nagy B, Brennan A, Brandtmuller A, Thomas SK, Sullivan SD, Akehurst R. Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in the UK using MMSE- and ADL-based models. Int J Geriatr Psychiatry. 2011;26(5):483–94.PubMed
224.
Revicki DA, Siddique J, Frank L, Chung JY, Green BL, Krupnick J, et al. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Arch Gen Psychiatry. 2005;62(8):868–75.PubMed
225.
Rive B, Grishchenko M, Guilhaume-Goulant C, Katona C, Livingston G, Lamure M, et al. Cost effectiveness of memantine in Alzheimer’s disease in the UK. J Med Econ. 2010;13(2):9.
226.
Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163(12):2080–9.PubMed
227.
Rost K, Pyne JM, Dickinson LM, LoSasso AT. Cost-effectiveness of enhancing primary care depression management on an ongoing basis. Ann Fam Med. 2005;3(1):7–14.PubMed
228.
Sava FA, Yates BT, Lupu V, Szentagotai A, David D. Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial. J Clin Psychol. 2009;65(1):36–52.PubMed
229.
Schoenbaum M, Unutzer J, Sherbourne C, Duan N, Rubenstein LV, Miranda J, et al. Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. JAMA. 2001;286(11):1325–30.PubMed
230.
Schoenbaum M, Miranda J, Sherbourne C, Duan N, Wells K. Cost-effectiveness of interventions for depressed Latinos. J Ment Health Policy Econ. 2004;7(2):69–76.PubMed
231.
Snedecor SJ, Botteman MF, Bojke C, Schaefer K, Barry N, Pickard AS. Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia. Sleep. 2009;32(6):817–24.PubMed
232.
Snedecor SJ, Botteman M, Schaefer K, Sarocco P, Barry N, Pickard AS. Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder. J Mental Health Policy Econ. 2010;13(1):8.
233.
Stevenson MD, Scope A, Sutcliffe PA, Booth A, Slade P, Parry G, et al. Group cognitive behavioural therapy for postnatal depression: a systematic review of clinical effectiveness, cost-effectiveness and value of information analyses. Health Technol Assess. 201014(44):1–107, iii–iv.
234.
Tran BX, Ohinmaa A, Duong AT, Do NT, Nguyen LT, Mills S, et al. Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam. AIDS Care. 2012;24(3):283–90.PubMed
235.
Treur M, Baca E, Bobes J, Canas F, Salvador L, Gonzalez B, et al. The cost-effectiveness of paliperidone extended release in Spain. J Med Econ. 2012;15(Suppl 1):26–34.PubMed
236.
Trivedi MH, Wan GJ, Mallick R, Chen J, Casciano R, Geissler EC, et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol. 2004;24(5):497–506.PubMed
237.
Wells KB, Schoenbaum M, Duan N, Miranda J, Tang L, Sherbourne C. Cost-effectiveness of quality improvement programs for patients with subthreshold depression or depressive disorder. Psychiatr Serv. 2007;58(10):1269–78.PubMed
238.
Weycker D, Taneja C, Edelsberg J, Erder MH, Schmitt FA, Setyawan J, et al. Cost-effectiveness of memantine in moderate-to-severe Alzheimer’s disease patients receiving donepezil. Curr Med Res Opin. 2007;23(5):1187–97.PubMed
239.
Wiley-Exley E, Domino ME, Maxwell J, Levkoff SE. Cost-effectiveness of integrated care for elderly depressed patients in the PRISM-E study. J Mental Health Policy Econ. 2009;12(4):8.
240.
Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res. 2004;71(1):155–65.PubMed
241.
Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord. 1998;48(1):25–36.PubMed
242.
Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, Weinstein MC. Health utilities in Alzheimer‘s disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37(1):27–32.PubMed
243.
Neumann PJ, Sandberg EA, Araki SS, Kuntz KM, Feeny D, Weinstein MC. A comparison of HUI2 and HUI3 utility scores in Alzheimer’s disease. Med Decis Making. 2000;20(4):413–22.PubMed
244.
Lenert LA, Sherbourne CD, Sugar C, Wells KB. Estimation of utilities for the effects of depression from the SF-12. Med Care. 2000;38(7):763–70.PubMed
245.
Olesen J, Gustavsson A, Svensson M, Wittchen HU, Jonsson B. The economic cost of brain disorders in Europe. Eur J Neurol. 2012;19(1):155–62.PubMed
246.
NICE. Guide to the methods of technology appraisal. London; 2008.
247.
Food and Drug Administration. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Rockville: Food and Drug Administration; 2009.
248.
Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5(1):1–30.PubMed
249.
Arnold D, Girling A, Stevens A, Lilford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009;339:b2688.PubMed
250.
Whitehurst DG, Bryan S. Another study showing that two preference-based measures of health-related quality of life (EQ-5D and SF-6D) are not interchangeable. But why should we expect them to be? Value Health. 2011;14(4):531–8.PubMed
251.
Wille N, Badia X, Bonsel G, Burstrom K, Cavrini G, Devlin N, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875–86.PubMed
252.
McCrone P, Patel A, Knapp M, Schene A, Koeter M, Amaddeo F, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ. 2009;12(1):27–31.PubMed
253.
Lamers LM, Bouwmans CA, van Straten A, Donker MC, Hakkaart L. Comparison of EQ-5D and SF-6D utilities in mental health patients. Health Econ. 2006;15(11):1229–36.PubMed
254.
Mann R, Gilbody S, Richards D. Putting the ‘Q’ in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol. 2009;44(7):569–78.PubMed
255.
Longworth L, Rowen DL. NICE DSU Technical Support Document 10: the use of mapping methods to estimate health utility values. 2011.
256.
Brazier J, Deverill M. A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. Health Econ. 1999;8(1):41–51.PubMed
257.
Knapp M, Mangalore R. The trouble with QALYs…. Epidemiol Psichiatr Soc. 2007;16(4):289–93.PubMed
258.
van de Willige G, Wiersma D, Nienhuis FJ, Jenner JA. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res. 2005;14(2):441–51.PubMed
259.
Versteegh MM, Leunis A, Uyl-de Groot CA, Stolk EA. Condition-specific preference-based measures: benefit or burden? Value Health. 2012;15(3):504–13.PubMed
260.
Chuang LH, Whitehead SJ. Mapping for economic evaluation. Br Med Bull. 2012;101:1–15.PubMed
261.
Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108.PubMed
262.
Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ. 1996;5(2):141–54.PubMed
263.
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.PubMed
264.
Feeny D, Furlong W, Torrance GW, Goldsmith CH, Zhu Z, DePauw S, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Med Care. 2002;40(2):113–28.PubMed
265.
Torrance GW, Feeny DH, Furlong WJ, Barr RD, Zhang Y, Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Med Care. 1996;34(7):702–22.PubMed
266.
Torrance GW, Furlong W, Feeny D, Boyle M. Multi-attribute preference functions. Health utilities index. Pharmacoeconomics. 1995;7(6):503–20.PubMed
267.
Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res. 1988;23(2):203–35.PubMed
268.
Albon E, Tsourapas A, Frew E, Davenport C, Oyebode F, Bayliss S, et al. Structural neuroimaging in psychosis: a systematic review and economic evaluation. Health Technol Assess. 2008;12(18):iii–iv, ix–163.
269.
Anderson L, Lewis G, Araya R, Elgie R, Harrison G, Proudfoot J, et al. Self-help books for depression: how can practitioners and patients make the right choice? Br J Gen Pract. 2005;55(514):387–92.PubMed
270.
Awad AG, Voruganti LN. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs. 2004;18(13):877–93.PubMed
271.
Barnett PG. The cost-effectiveness of methadone maintenance as a health care intervention. Addiction. 1999;94(4):479–88.PubMed
272.
Barrett B, Byford S, Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord. 2005;84(1):1–13.PubMed
273.
Basu A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res. 2004;71(2–3):445–62.PubMed
274.
Boudreau R, Moulton K, Cunningham J. Self-directed cognitive behavioural therapy for adults with diagnosis of depression: systematic review of clinical effectiveness, cost-effectiveness, and guidelines. CADTH Technol Overv. 2010;1(4):e0125.
275.
Brauer CA, Rosen AB, Greenberg D, Neumann PJ. Trends in the measurement of health utilities in published cost-utility analyses. Value Health. 2006;9(4):213–8.PubMed
276.
Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess. 2004;8(19):iii–iv, 1–187.
277.
Broadstock M, Brinson D, Weston A. The effectiveness of compulsory, residential treatment of chronic alcohol or drug addiction in non-offenders. HSAC Report. 2008;1(1).
278.
Burns T, Knapp M, Catty J, Healey A, Henderson J, Watt H, et al. Home treatment for mental health problems: a systematic review. Health Technol Assess. 2001;5(15):1–139.PubMed
279.
Cartwright WS. Cost-benefit analysis of drug treatment services: review of the literature*. J Ment Health Policy Econ. 2000;3(1):11–26.PubMed
280.
Christensen H, Pallister E, Smale S, Hickie IB, Calear AL. Community-based prevention programs for anxiety and depression in youth: a systematic review. J Prim Prev. 2010;31(3):139–70.PubMed
281.
Churchill R, Hunot V, Corney R, Knapp M, McGuire H, Tylee A, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. Health Technol Assess. 2001;5(35):1–173.PubMed
282.
Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer’s disease: a rapid and systematic review. Health Technol Assess. 2001;5(1):1–137.
283.
Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer’s disease: a systematic review. Int J Technol Assess Health Care. 2002 Summer;18(3):497–507.
284.
Conner TM, Crismon ML, Still DJ. A critical review of selected pharmacoeconomic analyses of antidepressant therapy. Ann Pharmacother. 1999;33(3):364–72.PubMed
285.
Cooke M, Chaboyer W, Hiratos MA. Music and its effect on anxiety in short waiting periods: a critical appraisal. J Clin Nurs. 2005;14(2):145–55.PubMed
286.
Croom KF, Plosker GL. Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics. 2003;21(16):1185–209.PubMed
287.
Croom KF, Plosker GL. Spotlight on the pharmacoeconomics of escitalopram in depression. CNS Drugs. 2004;18(7):469–73.PubMed
288.
Crott R, Gilis P. Economic comparisons of the pharmacotherapy of depression: an overview. Acta Psychiatr Scand. 1998;97(4):241–52.PubMed
289.
Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008;110(1–2):1–15.PubMed
290.
Davis R, Wilde MI. Sertraline. A pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics. 1996;10(4):409–31.PubMed
291.
Dean BB, Gerner D, Gerner RH. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder. Curr Med Res Opin. 2004;20(2):139–54.PubMed
292.
Donohue JM, Pincus HA. Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics. 2007;25(1):7–24.PubMed
293.
Dündar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, et al. Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation. Health Technol Assess. 2004;8(24):iii–x, 1–125.
294.
Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol. 2004;19(5):305–10.PubMed
295.
Engel SG, Adair CE, Las Hayas C, Abraham S. Health-related quality of life and eating disorders: a review and update. Int J Eat Disord. 2009;42(2):179–87.PubMed
296.
Evers SM, Van Wijk AS, Ament AJ. Economic evaluation of mental health care interventions. A review. Health Econ. 1997;6(2):161–77.PubMed
297.
Fenton C, Scott LJ. Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429–44.PubMed
298.
Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, et al. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess. 2010;14(3):1–157, iii.
299.
Foster GR, Scott DA, Payne S. The use of CT scanning in dementia. A systematic review. Int J Technol Assess Health Care. 1999 Spring;15(2):406–23.
300.
Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics. 1998;14(1):97–133.PubMed
301.
Frasch K, Neumann NU. Economic aspects of psychotherapy management in psychosomatics and psychiatry. A systematic survey of the literature. Nervenarzt. 1999;70(5):387–90.PubMed
302.
Garcia-Lizana F, Munoz-Mayorga I. Telemedicine for depression: a systematic review. Perspect Psychiatr Care. 2010;46(2):119–26.PubMed
303.
Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203–26.PubMed
304.
Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321(7273):1371–6.PubMed
305.
Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database Syst Rev. 2006(3):CD001851.
306.
Gilbody SM, House AO, Sheldon TA. Outcome measures and needs assessment tools for schizophrenia and related disorders. Cochrane Database Syst Rev. 2003(1):CD003081.
307.
Gilbody S, Bower P, Whitty P. Costs and consequences of enhanced primary care for depression: systematic review of randomised economic evaluations. Br J Psychiatry. 2006;189:297–308.PubMed
308.
Gordon L, Graves N, Hawkes A, Eakin E. A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol. Chronic Illn. 2007;3(2):101–29.PubMed
309.
Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics. 2005;115(5):e600–14.PubMed
310.
Griffiths KM, Christensen H. Internet-based mental health programs: a powerful tool in the rural medical kit. Aust J Rural Health. 2007;15(2):81–7.PubMed
311.
Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry. 2003;36(1):18–26.PubMed
312.
Hargreaves WA, Gibson PJ. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS Drugs. 2005;19(5):393–410.PubMed
313.
Höffler J, Trenckmann U, Graf von der Schulenburg JM. Health economics and evaluation of schizophrenic psychoses in Germany. Fortschr Neurol Psychiatr. 2000;68(Suppl 1):S7–12.PubMed
314.
Holm KJ, Jarvis B, Foster RH. Mirtazapine. A pharmacoeconomic review of its use in depression. Pharmacoeconomics. 2000;17(5):515–34.PubMed
315.
Höschl C, Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother. 2008;8(4):537–52.PubMed
316.
Hounsome N, Orrell M, Edwards RT. EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues. Value Health. 2011;14(2):390–9.PubMed
317.
Hulstaert F, Thiry N, Eyssen M, Vrijens F. Pharmaceutical and non-pharmaceutical interventions in Alzheimer’s Disease, a rapid assessment. KCE reports. 2009;111c.
318.
Huntley AL, Araya R, Salisbury C. Group psychological therapies for depression in the community: systematic review and meta-analysis. Br J Psychiatry. 2012;200(3):184–90.PubMed
319.
Husereau D, Wolfson C, Shukla VK. Drug treatments for Alzheimer’s disease: efficacy, outcome measurements and cost-effectiveness. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2001. Technology overview no. 4.
320.
Hyde C, Peters J, Bond M, Rogers G, Hoyle M, Anderson R, et al. Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model. Age Ageing. 2013;42(1):14–20.PubMed
321.
Jepson R, Di Blasi Z, Wright K, Ter Riet G. Scoping review of the effectiveness of mental services. York: NHS Centre for Reviews and Dissemination; 2001.
322.
Jönsson L. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer’s disease. Pharmacoeconomics. 2003;21(14):1025–37.PubMed
323.
Keating GM, Lyseng-Williamson KA. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics. 2010;28(3):231–54.PubMed
324.
Kirby J, Green C, Loveman E, Clegg A, Picot J, Takeda A, et al. A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer’s disease. Drugs Aging. 2006;23(3):227–40.PubMed
325.
Kisely SR, Campbell LA, Preston NJ. Compulsory community and involuntary outpatient treatment for people with severe mental disorders. Cochrane Database Syst Rev. 2011(2):CD004408.
326.
Konghom S, Verachai V, Srisurapanont M, Suwanmajo S, Ranuwattananon A, Kimsongneun N, et al. Treatment for inhalant dependence and abuse. Cochrane Database Syst Rev. 2010(12):CD007537.
327.
König HH, Friemel S. Health economics of psychological diseases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006;49(1):46–56.PubMed
328.
Konnopka A, Leichsenring F, Leibing E, König HH. Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect Disord. 2009;114(1–3):14–31.PubMed
329.
Kraemer KL. The cost-effectiveness and cost-benefit of screening and brief intervention for unhealthy alcohol use in medical settings. Subst Abus. 2007;28(3):67–77.PubMed
330.
Lamb HM, Goa KL. Rivastigmine: a pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics. 2001;19(3):303–18.PubMed
331.
Landon TM, Barlow DH. Cognitive-behavioral treatment for panic disorder: current status. J Psychiatr Pract. 2004;10(4):211–26.PubMed
332.
Laux G. Pharmacoeconomics of the new antidepressants and antipsychotics. Psychiatr Prax. 2003;30(Suppl 2):90–3.PubMed
333.
Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract. 2007;61(4):702–10.PubMed
334.
Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer’s disease. Health Technol Assess. 2006;10(1):iii–iv, ix–xi, 1–160.
335.
Lumley J, Austin MP, Mitchell C. Intervening to reduce depression after birth: a systematic review of the randomized trials. Int J Technol Assess Health Care. 2004 Spring;20(2):128–44.
336.
Lyseng-Williamson KA, Plosker GL. Galantamine: a pharmacoeconomic review of its use in Alzheimer’s disease. Pharmacoeconomics. 2002;20(13):919–42.PubMed
337.
McCrone P. Health economic measures in schizophrenia research. Br J Psychiatry Suppl. 2007;50:s42–5.PubMed
338.
McIntosh B, Clark M, Spry C. Benzodiazepines in older adults: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011.
339.
McKeage K. Memantine: a review of its use in moderate to severe Alzheimer’s disease. CNS Drugs. 2009;23(10):881–97.PubMed
340.
Mead N, Lester H, Chew-Graham C, Gask L, Bower P. Effects of befriending on depressive symptoms and distress: systematic review and meta-analysis. Br J Psychiatry. 2010;196(2):96–101.PubMed
341.
Meads C, Burls A, Gold L, Jobanputra P. In-patient versus out-patient care for eating disorders. Birmingham: Development and Evaluation Service Department of Public Health and Epidemiology; 1999.
342.
Morimoto T, Fukui T. Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals. J Epidemiol. 2002;12(2):160–78.PubMed
343.
Mujoomdar M, Spry C. Naltrexone for the treatment of alcohol dependence: a review of the clinical and cost-effectiveness. Ottawa: Health Technology Inquiry Service; 2009.
344.
Müller-Riemenschneider F, Rasch A, Bockelbrink A, Vauth C, Willich SN, Greiner W. Efficacy and effectiveness of smoking prevention programs. Köln: DIMDI; 2008.
345.
Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs. 2005;65(16):2379–404.PubMed
346.
Ndegwa S, Cunningham J. Naltrexone in combination with acamprosate for the treatment of alcohol dependence: a review of the clinical and cost-effectiveness. Ottawa: Health Technology Inquiry Service; 2009.
347.
Neumeyer-Gromen A, Lampert T, Stark K, Kallischnigg G. Disease management programs for depression: a systematic review and meta-analysis of randomized controlled trials. Med Care. 2004;42(12):1211–21.PubMed
348.
Ohinmaa A, Chatterley P, Nguyen T, Jacobs P. Telehealth in substance abuse and addiction: review of the literature on smoking, alcohol, drug abuse and gambling. Ottawa: Institute of Health Economics; 2010.
349.
Pirraglia PA, Rosen AB, Hermann RC, Olchanski NV, Neumann P. Cost-utility analysis studies of depression management: a systematic review. Am J Psychiatry. 2004;161(12):2155–62.PubMed
350.
Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer’s disease. Pharmacoeconomics. 2005;23(2):193–206.PubMed
351.
Pohar SL, Nkansah E. Cognitive behavioural therapy for post traumatic stress disorder: a review of the clinical and cost-effectiveness. Ottawa: Health Technology Inquiry Service; 2010.
352.
Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer’s disease: a systematic review of cost-effectiveness analyses. Drugs. 2012;72(6):789–802.PubMed
353.
Radlberger P, Zechmeister I, Tarquin M. Health economic evaluations in psychiatry of children and adolescents: a systematic review. Wien: Ludwig Boltzmann Institute for Health Technology Assessment; 2009.
354.
Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res. 1999;1(35 Suppl):S101–9.
355.
Riemsma RP, Forbes CA, Glanville JM, Eastwood AJ, Kleijnen J. General health status measures for people with cognitive impairment: learning disability and acquired brain injury. Health Technol Assess. 2001;5(6):1–100.
356.
Rizzo M, Creed F, Goldberg D, Meader N, Pilling S. A systematic review of non-pharmacological treatments for depression in people with chronic physical health problems. J Psychosom Res. 2011;71(1):18–27.PubMed
357.
Robinson L, Hutchings D, Corner L, Beyer F, Dickinson H, Vanoli A, et al. A systematic literature review of the effectiveness of non-pharmacological interventions to prevent wandering in dementia and evaluation of the ethical implications and acceptability of their use. Health Technol Assess. 2006;10(26):iii, ix–108.
358.
Rodgers M, Asaria M, Walker S, McMillan D, Lucock M, Harden M, et al. The clinical effectiveness and cost-effectiveness of low-intensity psychological interventions for the secondary prevention of relapse after depression: a systematic review. Health Technol Assess. 2012;16(28):1–130.PubMed
359.
Romeo R, Byford S, Knapp M. Annotation: economic evaluations of child and adolescent mental health interventions: a systematic review. J Child Psychol Psychiatry. 2005;46(9):919–30.PubMed
360.
Rosenberg R. Outcome measures of antidepressive therapy. Acta Psychiatr Scand Suppl. 2000;402:41–4.PubMed
361.
Ruger JP, Emmons KM. Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review. Value Health. 2008;11(2):180–90.PubMed
362.
Schlander M. Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness. Eur Child Adolesc Psychiatry. 2007;16(7):421–9.PubMed
363.
Schlander M. The pharmaceutical economics of child psychiatric drug treatment. Curr Pharm Des. 2010;16(22):2443–61.PubMed
364.
Schlander M, Trott GE, Schwarz O. The health economics of attention deficit hyperactivity disorder in Germany. Part 2: therapeutic options and their cost-effectiveness. Nervenarzt. 2010;81(3):301–14.PubMed
365.
Shah A, Murthy S, Suh GK. Is mental health economics important in geriatric psychiatry in developing countries? Int J Geriatr Psychiatry. 2002;17(8):758–64.PubMed
366.
Shearer J, Green C, Ritchie CW, Zajicek JP. Health state values for use in the economic evaluation of treatments for Alzheimer’s disease. Drugs Aging. 2012;29(1):31–43.PubMed
367.
Shukla VK, Otten N, Coyle D. Drug treatments for Alzheimer’s disease. III. A review of pharmacoeconomic evaluations. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2000. Technology report no. 11.
368.
Simoens S, Ludbrook A, Matheson C, Bond C. Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology. Drug Alcohol Depend. 2006;84(1):28–39.PubMed
369.
Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010;55(3):126–35.PubMed
370.
Steffen S, Kosters M, Becker T, Puschner B. Discharge planning in mental health care: a systematic review of the recent literature. Acta Psychiatr Scand. 2009;120(1):1–9.PubMed
371.
Thota AB, Sipe TA, Byard GJ, Zometa CS, Hahn RA, McKnight-Eily LR, et al. Collaborative care to improve the management of depressive disorders: a community guide systematic review and meta-analysis. Am J Prev Med. 2012;42(5):525–38.PubMed
372.
Turner R. Quality of life: experience with sertraline. Int Clin Psychopharmacol. 1994;9(Suppl 3):27–31.PubMed
373.
van Steenbergen-Weijenburg KM, van der Feltz-Cornelis CM, Horn EK, van Marwijk HW, Beekman AT, Rutten FF, et al. Cost-effectiveness of collaborative care for the treatment of major depressive disorder in primary care. A systematic review. BMC Health Serv Res. 2010;10:19.PubMed
374.
Warner KE. Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage. Pharmacoeconomics. 1997;11(6):538–49.PubMed
375.
Waugh J, Goa KL. Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17(5):343–62.PubMed
376.
Wimo A. Clinical and economic outcomes—friend or foe? Int Psychogeriatr. 2007;19(3):497–507.PubMed
377.
Armstrong EP, Malone DC, Erder MH. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder. Curr Med Res Opin. 2008;24(4):1115–21.PubMed
378.
Bolin K, Wilson K, Benhaddi H, de Nigris E, Marbaix S, Mork AC, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries. Eur J Public Health. 2009;19(6):650–4.PubMed
379.
Davies A, Vardeva K, Loze JY, L’Italien GJ, Sennfalt K, Baardewijk M. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK. Curr Med Res Opin. 2008;24(11):3275–85.PubMed
380.
François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. JME. 2002;73(5):91–107.
381.
Gustavsson A, Van Der Putt R, Jonsson L, McShane R. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer’s disease and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2009;24(10):1072–8.PubMed
382.
Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C. Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer’s disease in the Netherlands. Neuropsychiatr Dis Treat. 2011;7:313–7.PubMed
383.
Mortimer D, Segal L. Economic evaluation of interventions for problem drinking and alcohol dependence: cost per QALY estimates. Alcohol Alcohol. 2005;40(6):549–55.PubMed
384.
Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Arch Gen Psychiatry. 1999;56(6):565–72.PubMed
385.
Salize HJ, Jacke C, Kief S, Franz M, Mann K. Treating alcoholism reduces financial burden on care-givers and increases quality-adjusted life years. Addiction. 2013;108(1):62–70.PubMed
386.
Vanagas G, Padaiga Z, Bagdonas E. Cost-utility analysis of methadone maintenance treatment in Lithuania. Medicina (Kaunas). 2010;46(4):286–92.PubMed
387.
van den Berg M, van Baal PH, Tariq L, Schuit AJ, de Wit GA, Hoogenveen RT. The cost-effectiveness of increasing alcohol taxes: a modelling study. BMC Med. 2008;6:36.PubMed
388.
Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess. 2007;11(6):iii–iv, 1–85.
389.
Bagnall AM, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess. 2003;7(13):1–193.PubMed
390.
Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1–171, iii–iv.
391.
Dretzke J, Frew E, Davenport C, Barlow J, Stewart-Brown S, Sandercock J, et al. The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in children. Health Technol Assess. 2005;9(50):iii, ix–x, 1–233.
392.
Hatziandreu EJ, Brown RE, Revicki DA, Turner R, Martindale J, Levine S, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics. 1994;5(3):249–68.PubMed
393.
Lynch FL, Striegel-Moore RH, Dickerson JF, Perrin N, Debar L, Wilson GT, et al. Cost-effectiveness of guided self-help treatment for recurrent binge eating. J Consult Clin Psychol. 2010;78(3):322–33.PubMed
394.
Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27(6):669–76.PubMed
395.
Stephen JH, Halpern CH, Barrios CJ, Balmuri U, Pisapia JM, Wolf JA, et al. Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis. Addiction. 2012;107(3):624–34.PubMed
396.
Zhang M, Owen RR, Pope SK, Smith GR. Cost-effectiveness of clozapine monitoring after the first 6 months. Arch Gen Psychiatry. 1996;53(10):954–8.PubMed
397.
Kasteng F, Eriksson J, Sennfalt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011;124(3):214–25.PubMed
398.
Katon W, Russo J, Lin EH, Schmittdiel J, Ciechanowski P, Ludman E, et al. Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial. Arch Gen Psychiatry. 2012;69(5):506–14.PubMed
Metadata
Title
The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review
Authors
Michael Sonntag
Hans-Helmut König
Alexander Konnopka
Publication date
01-12-2013
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 12/2013
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0107-9

Other articles of this Issue 12/2013

PharmacoEconomics 12/2013 Go to the issue

Commentary

Search MEDLINE for Economic Evaluations: Tips to Translate an OVID Strategy into a PubMed One

Original Research Article

A Closer Look at Decision and Analyst Error by Including Nonlinearities in Discrete Choice Models: Implications on Willingness-to-Pay Estimates Derived from Discrete Choice Data in Healthcare

Systematic Review

Cost Effectiveness of Medication Adherence-Enhancing Interventions: A Systematic Review of Trial-Based Economic Evaluations

Review Article

Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal

Practical Application

How to Include Informal Care in Economic Evaluations

Acknowledgement to Referees

Acknowledgments